{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:13:59Z","timestamp":1793747639806,"version":"4.6.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Macular Society Seedcorn Grant University of Oxford Clarendon-Keble de Breyne Ramsay Scholarship","id":[{"id":"https:\/\/ror.org\/052gg0110","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Macular Society Seedcorn Grant NIHR Oxford Biomedical Research Centre (BRC) Wellcome Trust","id":[{"id":"https:\/\/ror.org\/00aps1a34","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Macular Society Seedcorn Grant CRN-NIHR Thames Valley South Midlands Network","id":[{"id":"https:\/\/ror.org\/02j172648","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Landmark studies reported on faricimab efficacy and safety predominantly in treatment na\u00efve patients, but outcomes following switch from other anti-VEGF therapies are lacking. We evaluated patients switched to faricimab who had\u00a0previously shown a partial response to other anti-VEGF injections for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective study at the Oxford Eye Hospital. Patients switched to faricimab from January to April 2023 with six months follow-up were identified via electronic medical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 116 patients (151 eyes) were included. In 88 patients with nAMD (107 eyes), mean visual acuity remained stable: 62\u00b117 ETDRS letters at baseline; 62\u00b118 at six months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). Central subfield thickness (CST) reduced from 294\u2009\u00b1\u200973\u2009\u03bcm to 270\u2009\u00b1\u200953\u2009\u03bcm (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) at six months. Subretinal or intraretinal fluid was present in 102 eyes (95%) at baseline and 75 eyes (70%) at follow-up (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Pigment epithelial detachment height decreased from 233\u2009\u00b1\u2009134\u2009\u03bcm to 188\u2009\u00b1\u2009147\u2009\u03bcm (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Mean treatment interval increased by 1.7 weeks (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) and was extended in 61 eyes (57%) at six months. In 28 patients with DMO (44 eyes), visual acuity remained stable: 69\u2009\u00b1\u200915 letters at baseline; 70\u00b115 at six months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). CST reduced from 355\u2009\u00b1\u200987\u2009\u03bcm to 317\u2009\u00b1\u200982\u2009\u03bcm (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Mean treatment interval increased by 1.4 weeks (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) and was extended in 21 eyes (46%) by six months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching to faricimab in treatment resistant eyes led to improved anatomical response and extended treatment interval in a significant proportion of patients. Ongoing review of real-world data will inform longer-term outcomes of safety and effectiveness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-024-03364-y","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T12:01:55Z","timestamp":1728648115000},"page":"3569-3577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1395-6875","authenticated-orcid":false,"given":"Grace A.","family":"Borchert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A.","family":"Kiire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh M.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handan","family":"Akil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Gkika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Dominik","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0065-9131","authenticated-orcid":false,"given":"Kanmin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9956-6412","authenticated-orcid":false,"given":"Jasmina","family":"Cehajic-Kapetanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3096-4682","authenticated-orcid":false,"given":"Robert E.","family":"MacLaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0351-6673","authenticated-orcid":false,"given":"Peter","family":"Charbel Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Downes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4455-2814","authenticated-orcid":false,"given":"Samantha R.","family":"De Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"key":"3364_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2022.100114","volume":"2","author":"CP Creuzot-Garcher","year":"2022","unstructured":"Creuzot-Garcher CP, Srour M, Baudin F, Daien V, Dot C, Nghiem-Buffet S, et al. Incidence and prevalence of neovascular age-related macular degeneration in France between 2008 and 2018: the LANDSCAPE study. Ophthalmol Sci. 2022;2:100114.","journal-title":"Ophthalmol Sci"},{"key":"3364_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","volume":"2","author":"R Lee","year":"2015","unstructured":"Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2:17.","journal-title":"Eye Vis (Lond)"},{"key":"3364_CR3","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2016;8:1265\u201388.","journal-title":"EMBO Mol Med"},{"key":"3364_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaophthalmol.2019.4557","volume":"138","author":"K Mulligan","year":"2020","unstructured":"Mulligan K, Seabury SA, Dugel PU, Blim JF, Goldman DP, Humayun MS. Economic value of anti-vascular endothelial growth factor treatment for patients with wet age-related macular degeneration in the United States. JAMA Ophthalmol. 2020;138:40\u20137.","journal-title":"JAMA Ophthalmol"},{"key":"3364_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","volume":"82","author":"M Shirley","year":"2022","unstructured":"Shirley M. Faricimab: first approval. Drugs. 2022;82:825\u201330.","journal-title":"Drugs"},{"key":"3364_CR6","unstructured":"MHRA approves faricimab through international work-sharing initiative 2022 [Available from: https:\/\/www.gov.uk\/government\/news\/mhra-approves-faricimab-through-international-work-sharing-initiative]."},{"key":"3364_CR7","unstructured":"European Medicines Agency. Vabysmo 2022 [Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vabysmo]."},{"key":"3364_CR8","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.2147\/DDDT.S368963","volume":"16","author":"AA Nair","year":"2022","unstructured":"Nair AA, Finn AP, Sternberg P Jr. Spotlight on faricimab in the treatment of wet age-related macular degeneration: design, development and place in therapy. Drug Des Devel Ther. 2022;16:3395\u2013400.","journal-title":"Drug Des Devel Ther"},{"key":"3364_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"3364_CR10","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","volume":"138","author":"J Sahni","year":"2020","unstructured":"Sahni J, Dugel PU, Patel SS, Chittum ME, Berger B, Del Valle Rubido M, et al. Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;138:955\u201363.","journal-title":"JAMA Ophthalmol"},{"key":"3364_CR11","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","volume":"138","author":"AM Khanani","year":"2020","unstructured":"Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, et al. Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial. JAMA Ophthalmol. 2020;138:964\u201372.","journal-title":"JAMA Ophthalmol"},{"key":"3364_CR12","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","volume":"126","author":"J Sahni","year":"2019","unstructured":"Sahni J, Patel SS, Dugel PU, Khanani AM, Jhaveri CD, Wykoff CC, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019;126:1155\u201370.","journal-title":"Ophthalmology"},{"key":"3364_CR13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399:741\u201355.","journal-title":"Lancet"},{"key":"3364_CR14","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/eye.2015.48","volume":"29","author":"WM Amoaku","year":"2015","unstructured":"Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015;29:721\u201331.","journal-title":"Eye (Lond)"},{"key":"3364_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100906","volume":"82","author":"PS Mettu","year":"2021","unstructured":"Mettu PS, Allingham MJ, Cousins SW. Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res. 2021;82:100906.","journal-title":"Prog Retin Eye Res"},{"key":"3364_CR16","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","volume":"37","author":"PE Stanga","year":"2023","unstructured":"Stanga PE, Valent\u00edn-Bravo FJ, Stanga SEF, Reinstein UI, Pastor-Idoate S, Downes SM. Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye (Lond). 2023;37:3282\u20139.","journal-title":"Eye (Lond)"},{"key":"3364_CR17","unstructured":"Zuber-Laskawiec K, Kubicka-Trzaska A, Karska-Basta I, Pociej-Marciak W, Romanowska-Dixon B. Non-responsiveness and tachyphylaxis to anti-vascular endothelial growth factor treatment in naive patients with exudative age-related macular degeneration. J Physiol Pharmacol. 2019;70:779\u201385."},{"key":"3364_CR18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.oret.2018.01.006","volume":"2","author":"TA Ciulla","year":"2018","unstructured":"Ciulla TA, Huang F, Westby K, Williams DF, Zaveri S, Patel SC. Real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States. Ophthalmol Retin. 2018;2:645\u201353.","journal-title":"Ophthalmol Retin"},{"key":"3364_CR19","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1001\/jamaophthalmol.2018.2019","volume":"136","author":"L Lor\u00e9s-Motta","year":"2018","unstructured":"Lor\u00e9s-Motta L, Riaz M, Grunin M, Corominas J, van Asten F, Pauper M, et al. Association of genetic variants with response to anti-vascular endothelial growth factor therapy in age-related macular degeneration. JAMA Ophthalmol. 2018;136:875\u201384.","journal-title":"JAMA Ophthalmol"},{"key":"3364_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100076","volume":"1","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Guymer RH, Basu K, Boston H, Heier JS, Korobelnik JF, et al. TENAYA and LUCERNE: rationale and design for the phase 3 clinical trials of faricimab for neovascular age-related macular degeneration. Ophthalmol Sci. 2021;1:100076.","journal-title":"Ophthalmol Sci"},{"key":"3364_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100111","volume":"2","author":"N Eter","year":"2022","unstructured":"Eter N, Singh RP, Abreu F, Asik K, Basu K, Baumal C, et al. YOSEMITE and RHINE: phase 3 randomized clinical trials of faricimab for diabetic macular edema: study design and rationale. Ophthalmol Sci. 2022;2:100111.","journal-title":"Ophthalmol Sci"},{"key":"3364_CR22","doi-asserted-by":"crossref","unstructured":"Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, et al. Faricimab treat-and-extend for diabetic macular edema: 2-year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology. 2023;131:708\u201323.","DOI":"10.1016\/j.ophtha.2023.12.026"},{"key":"3364_CR23","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2147\/OPTH.S424315","volume":"17","author":"RB Rush","year":"2023","unstructured":"Rush RB. One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:2201\u20138.","journal-title":"Clin Ophthalmol"},{"key":"3364_CR24","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.2147\/OPTH.S395279","volume":"16","author":"RB Rush","year":"2022","unstructured":"Rush RB, Rush SW. Intravitreal faricimab for aflibercept-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2022;16:4041\u20136.","journal-title":"Clin Ophthalmol"},{"key":"3364_CR25","doi-asserted-by":"crossref","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study \u2013 6 month results. Eye. 2023;37:3574\u201381.","DOI":"10.1038\/s41433-023-02553-5"},{"key":"3364_CR26","doi-asserted-by":"crossref","unstructured":"Grimaldi G, Cancian G, Rizzato A, Casanova A, Perruchoud-Ader K, Clerici M, et al. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study. Graefes Arch Clin Exp Ophthalmol. 2023;262:1151\u20139.","DOI":"10.1007\/s00417-023-06319-3"},{"key":"3364_CR27","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2147\/OPTH.S409822","volume":"17","author":"EH Leung","year":"2023","unstructured":"Leung EH, Oh DJ, Alderson SE, Bracy J, McLeod M, Perez LI, et al. Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration. Clin Ophthalmol. 2023;17:1287\u201393.","journal-title":"Clin Ophthalmol"},{"key":"3364_CR28","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1007\/s40123-023-00779-w","volume":"12","author":"S Inoda","year":"2023","unstructured":"Inoda S, Takahashi H, Takahashi R, Hashimoto Y, Yoshida H, Takahashi H, et al. Visual and anatomical outcomes after initial intravitreal faricimab injection for neovascular age-related macular degeneration in patients with prior treatment history. Ophthalmol Ther. 2023;12:2703\u201312.","journal-title":"Ophthalmol Ther"},{"key":"3364_CR29","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.3390\/jcm12155145","volume":"12","author":"M Kishi","year":"2023","unstructured":"Kishi M, Miki A, Kamimura A, Okuda M, Matsumiya W, Imai H, et al. Short-term outcomes of faricimab treatment in aflibercept-refractory eyes with neovascular age-related macular degeneration. J Clin Med. 2023;12:5145.","journal-title":"J Clin Med"},{"key":"3364_CR30","doi-asserted-by":"crossref","unstructured":"Kataoka K, Itagaki K, Hashiya N, Wakugawa S, Tanaka K, Nakayama M, et al. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2023;262:43\u201351.","DOI":"10.1007\/s00417-023-06222-x"},{"key":"3364_CR31","doi-asserted-by":"crossref","unstructured":"Szigiato A, Mohan N, Talcott KE, Mammo DA, Babiuch AS, Kaiser PK, et al. Short-term outcomes of faricimab in patients with neovascular age-related macular degeneration on prior anti-VEGF therapy. Ophthalmol Retina. 2023;8:10\u20137.","DOI":"10.1016\/j.oret.2023.08.018"},{"key":"3364_CR32","doi-asserted-by":"crossref","unstructured":"Pandit SA, Momenaei B, Wakabayashi T, Mansour HA, Vemula S, Durrani AF, et al. Real-world outcomes of faricimab in patients with previously treated neovascular age-related macular degeneration. Ophthalmol Retina. 2023;8:360\u20136.","DOI":"10.1016\/j.oret.2023.10.018"},{"key":"3364_CR33","unstructured":"Talks J, De Salvo G, Patel P, de Silva S, Gale R, Varma D, et al. FARWIDE-nAMD: early treatment patterns of faricimab among neovascular age-related macular degeneration (nAMD) patients in the UK. EURETINA; Netherlands 2023."},{"key":"3364_CR34","doi-asserted-by":"crossref","unstructured":"Raimondi R, Falfeli T, Bogdanova-Bennet A, Varma D, Habib M, Kotagiri A, et al. Real-world outcomes of treatment resistant neovascular-age related macular degeneration switched from Aflibercept to Faricimab. Ophthalmol Retina. 2023;8:537\u201344.","DOI":"10.1016\/j.oret.2023.11.015"},{"key":"3364_CR35","doi-asserted-by":"publisher","unstructured":"Goodchild C, Bailey C, Soto Hernaez J, Ahmed E, Salvatore S Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy. Eye (Lond). 2024; https:\/\/doi.org\/10.1038\/s41433-024-03218-7. Online ahead of print.","DOI":"10.1038\/s41433-024-03218-7"},{"key":"3364_CR36","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2147\/OPTH.S463624","volume":"18","author":"NQX Quah","year":"2024","unstructured":"Quah NQX, Javed K, Arbi L, Hanumunthadu D. Real-world outcomes of faricimab treatment for neovascular age-related macular degeneration and diabetic macular edema. Clin Ophthalmol. 2024;18:1479\u201390.","journal-title":"Clin Ophthalmol"},{"key":"3364_CR37","first-page":"478","volume":"11","author":"DR Muth","year":"2024","unstructured":"Muth DR, Fasler KF, Kvanta A, Rejdak M, Blaser F, Zweifel SA. Real-world weekly efficacy analysis of faricimab in patients with age-related macular degeneration. Bioeng (Basel). 2024;11:478.","journal-title":"Bioeng (Basel)"},{"key":"3364_CR38","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3390\/pharmaceutics16040470","volume":"16","author":"W Aljundi","year":"2024","unstructured":"Aljundi W, Daas L, Suffo S, Seitz B, Abdin AD. First-year real-life experience with intravitreal faricimab for refractory neovascular age-related macular degeneration. Pharmaceutics. 2024;16:470.","journal-title":"Pharmaceutics"},{"key":"3364_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-59632-0","volume":"14","author":"F Eckardt","year":"2024","unstructured":"Eckardt F, Lorger A, Hafner M, Klaas JE, Schworm B, Kreutzer TC, et al. Retinal and choroidal efficacy of switching treatment to faricimab in recalcitrant neovascular age related macular degeneration. Sci Rep. 2024;14:9600.","journal-title":"Sci Rep."},{"key":"3364_CR40","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s00417-024-06421-0","volume":"262","author":"M Schneider","year":"2024","unstructured":"Schneider M, Bjerager J, Hodzic-Hadzibegovic D, Klefter ON, Subhi Y, Hajari J. Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262:2153\u201362.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3364_CR41","first-page":"193","volume":"14","author":"B Ng","year":"2024","unstructured":"Ng B, Kolli H, Ajith Kumar N, Azzopardi M, Logeswaran A, Buensalido J, et al. Real-world data on faricimab switching in treatment-refractory neovascular age-related macular degeneration. Life (Basel). 2024;14:193.","journal-title":"Life (Basel)"},{"key":"3364_CR42","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.2147\/OPTH.S424314","volume":"17","author":"RB Rush","year":"2023","unstructured":"Rush RB. One year results of faricimab for aflibercept-resistant diabetic macular edema. Clin Ophthalmol. 2023;17:2397\u2013403.","journal-title":"Clin Ophthalmol"},{"key":"3364_CR43","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.2147\/OPTH.S381503","volume":"16","author":"RB Rush","year":"2022","unstructured":"Rush RB, Rush SW. Faricimab for treatment-resistant diabetic macular edema. Clin Ophthalmol. 2022;16:2797\u2013801.","journal-title":"Clin Ophthalmol"},{"key":"3364_CR44","unstructured":"Bailey C, Peto T, Downey L, Kiire C, Pearce I, Reynolds R, et al. FARWIDE-DME: early treatment patterns of faricimab among DME patients in the UK. EURETINA; Netherlands 2023."},{"key":"3364_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10792-024-03226-2","volume":"44","author":"F Pichi","year":"2024","unstructured":"Pichi F, Abdi A, Aljneibi S, El Ghrably I, Agarwal A, Ghazi NG. Switch to faricimab after initial treatment with aflibercept in eyes with diabetic macular edema. Int Ophthalmol. 2024;44:275.","journal-title":"Int Ophthalmol"},{"key":"3364_CR46","first-page":"732","volume":"60","author":"T Tatsumi","year":"2024","unstructured":"Tatsumi T, Kaiho T, Iwase T, Miura G, Shimizu D, Niizawa T, et al. Treatment effects of switching to faricimab in eyes with diabetic macular edema refractory to aflibercept. Med (Kaunas). 2024;60:732.","journal-title":"Med (Kaunas)"},{"key":"3364_CR47","doi-asserted-by":"crossref","unstructured":"Durrani AF, Momenaei B, Wakabayashi T, Vemula S, Pandit SA, Hsu J, et al. Conversion to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular oedema. Br J Ophthalmol. 2024;108:1257\u201362.","DOI":"10.1136\/bjo-2023-324394"},{"key":"3364_CR48","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.2147\/OPTH.S231801","volume":"15","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Russell MW, Aziz AA, Danzig CJ, Weng CY, Eichenbaum DA, et al. Angiopoietins as potential targets in management of retinal disease. Clin Ophthalmol. 2021;15:3747\u201355.","journal-title":"Clin Ophthalmol"},{"key":"3364_CR49","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s13300-022-01326-9","volume":"13","author":"JD Collazos-Alem\u00e1n","year":"2022","unstructured":"Collazos-Alem\u00e1n JD, Gnecco-Gonz\u00e1lez S, Jaramillo-Zarama B, Jim\u00e9nez-Mora MA, Mendivil CO. The role of angiopoietins in neovascular diabetes-related retinal diseases. Diabetes Ther. 2022;13:1811\u201321.","journal-title":"Diabetes Ther"},{"key":"3364_CR50","doi-asserted-by":"publisher","first-page":"a006550","DOI":"10.1101\/cshperspect.a006650","volume":"2","author":"G Thurston","year":"2012","unstructured":"Thurston G, Daly C. The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway. Cold Spring Harb Perspect Med. 2012;2:a006550.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3364_CR51","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1080\/13543784.2019.1667333","volume":"28","author":"RM Hussain","year":"2019","unstructured":"Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA. Tie-2\/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opin Investig Drugs. 2019;28:861\u20139.","journal-title":"Expert Opin Investig Drugs"},{"key":"3364_CR52","first-page":"31","volume":"2","author":"P Yerramothu","year":"2018","unstructured":"Yerramothu P. New Therapies of Neovascular AMD-Beyond Anti-VEGFs. Vis (Basel). 2018;2:31.","journal-title":"Vis (Basel)"},{"key":"3364_CR53","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s00125-016-3974-8","volume":"59","author":"B Bahrami","year":"2016","unstructured":"Bahrami B, Zhu M, Hong T, Chang A. Diabetic macular oedema: pathophysiology, management challenges and treatment resistance. Diabetologia. 2016;59:1594\u2013608.","journal-title":"Diabetologia"},{"key":"3364_CR54","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1007\/s00417-020-05059-y","volume":"259","author":"E Granstam","year":"2021","unstructured":"Granstam E, Aurell S, Sj\u00f6vall K, Paul A. Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting. Graefes Arch Clin Exp Ophthalmol. 2021;259:2085\u201393.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3364_CR55","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1136\/bjophthalmol-2013-304829","volume":"98","author":"WB Messenger","year":"2014","unstructured":"Messenger WB, Campbell JP, Faridi A, Shippey L, Bailey ST, Lauer AK, et al. Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2014;98:1205\u20137.","journal-title":"Br J Ophthalmol"},{"key":"3364_CR56","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1097\/IAE.0000000000001637","volume":"38","author":"CS Lee","year":"2018","unstructured":"Lee CS, Kim AJ, Baughman D, Egan C, Bailey C, Johnston RL, et al. Visual acuity improvement when switching from ranibizumab to aflibercept is not sustained. Retina. 2018;38:951\u20136.","journal-title":"Retina"},{"key":"3364_CR57","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1136\/bjophthalmol-2019-314251","volume":"104","author":"RP Gale","year":"2020","unstructured":"Gale RP, Pearce I, Eter N, Ghanchi F, Holz FG, Schmitz-Valckenberg S, et al. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. Br J Ophthalmol. 2020;104:493\u20139.","journal-title":"Br J Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03364-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03364-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03364-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T23:30:40Z","timestamp":1733441440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-024-03364-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":57,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3364"],"URL":"https:\/\/doi.org\/10.1038\/s41433-024-03364-y","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]},"assertion":[{"value":"23 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SDS has served on Advisory Boards for Roche, AbbVie and received educational travel grants from Bayer\u00a0and Roche. CK has served on Advisory Boards for and\/or received speaker fees, travel grants, or attended educational events sponsored by Bayer, Alimera Sciences and Roche. No relevant conflicts of interest for GAB, NMS, HA, TG, MDF, KX, JC-K, REM, PCI, and SMD.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}